18:16 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Real-world data play RDMD raises $3M seed round

RDMD (San Francisco, Calif.) raised $3 million on Aug. 20 in a seed round led by new investor Lux Capital, with participation from existing investor Village Globe and new investors First Round's Healthcare Co-Op, Garuda...
11:02 , Aug 20, 2018 |  BC Extra  |  Financial News

Real-world data play RDMD raises $3M seed round

RDMD (San Francisco, Calif.) raised $3 million in a seed round led by new investor Lux Capital, with participation from existing investor Village Globe and new investors First Round's Healthcare Co-Op, Garuda and Shasta Ventures. Several...
15:35 , Jul 27, 2018 |  BC Week In Review  |  Company News

GSK, 23andMe partner on target, drug discovery

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on July 25, when the pharma provided an R&D update, announced 2Q18...
23:14 , Jul 25, 2018 |  BC Extra  |  Company News

GSK's near-term R&D prospects include an ADC as it pivots to immunology

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on Wednesday, when the pharma provided an R&D update, announced 2Q18 earnings...
00:43 , Jun 29, 2018 |  BC Innovations  |  Product R&D

Highly personal

Pact Pharma Inc. has raised $120 million in venture financing to tackle one of the most complex forms of personalized medicine proposed to date: neoantigen-targeted T cells. Backed by Alphabet Inc.’s GV, the company is...
21:46 , May 31, 2018 |  BC Innovations  |  Tools & Techniques

Bundled inheritance

Two new studies showcase how researchers are gleaning more from GWAS by combining risk factors rather than looking at the risks from individual mutations. The results could add numbers to the contribution of nature vs....
20:45 , May 30, 2018 |  BC Extra  |  Company News

Management tracks: Zafgen, Rigel

Metabolic disease company Zafgen Inc. (NASDAQ:ZFGN) hired Brian McVeigh as CBO. He was VP of worldwide business development transactions and investment management at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Immunology and cancer company Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) hired...
18:59 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

FDA approves 23andMe's direct-to-consumer test for cancer risk

23andMe Inc. (Mountain View, Calif.) said FDA authorized its direct-to-consumer BRCA1/BRCA2 (Selected Variants) Genetic Health Risk (GHR) Report to provide patients with genetic information on their cancer risk. The approval, which came via FDA's de...
23:26 , Mar 6, 2018 |  BC Extra  |  Company News

FDA approves 23andMe's direct-to-consumer test for cancer risk

23andMe Inc. (Mountain View, Calif.) said FDA authorized its direct-to-consumer BRCA1/BRCA2 (Selected Variants) Genetic Health Risk (GHR) Report to provide patients with genetic information on their cancer risk. The approval, which came via FDA's de...
00:34 , Nov 7, 2017 |  BC Extra  |  Politics & Policy

FDA to exempt some genetic tests from premarket review

FDA implemented a new regulatory pathway for genetic health risk (GHR) assessments on Monday by classifying all GHR tests as low to moderate risk class II devices with “special controls.” By doing so, the agency...